case_images: PMC1784092_01
case_images: Axial MRI of the left popliteal fossa showing two enlarged nodes in close proximity to the popliteal vessels.
case_images: 1477-7819-5-8-1.jpg
case_images: PMC1784092_01_1477-7819-5-8-1.jpg
case_images: F1
case_images: Ultrasounds study (US) and magnetic resonance imaging (MRI) (Figure 1, 2) revealed evidence of two involved nodes in the popliteal fossa measuring respectively 2.7 x 1.7 and 2.3 x 1.5 cm, positive for metastatic melanoma by FNAC.
case_images: Sagittal MRI of the left popliteal fossa showing two involved nodes anterior to the neurovascular bundle.
case_images: 1477-7819-5-8-2.jpg
case_images: PMC1784092_01_1477-7819-5-8-2.jpg
case_images: F2
case_images: Ultrasounds study (US) and magnetic resonance imaging (MRI) (Figure 1, 2) revealed evidence of two involved nodes in the popliteal fossa measuring respectively 2.7 x 1.7 and 2.3 x 1.5 cm, positive for metastatic melanoma by FNAC.
case_images: PET whole-body showing systemic uptake of the radiotracer.
case_images: 1477-7819-5-8-3.jpg
case_images: PMC1784092_01_1477-7819-5-8-3.jpg
case_images: F3
case_images: In the October 2005 during follow-up control, whole body positron emission tomography (PET) showed uptake of the radiotracer in the superficial tissues of the trunk, left thigh, left leg and in the abdomino-pelvic area (Figure 3).
case_images: PET whole-body performed after chemotherapy, showing no signs of systemic disease.
case_images: 1477-7819-5-8-4.jpg
case_images: PMC1784092_01_1477-7819-5-8-4.jpg
case_images: F4
case_images: After surgery he received chemotherapy (fotemustine 100 mg/m2 plus dacarbazine 900 mg/m2 intravenously, every three weeks, for a total of nine cycles) and in September 2006 the patient is alive with no evidence of disease (Figure 4, 5).
case_images: PET whole-body performed after chemotherapy, showing no evidence of disease in the left popliteal fossa.
case_images: 1477-7819-5-8-5.jpg
case_images: PMC1784092_01_1477-7819-5-8-5.jpg
case_images: F5
case_images: After surgery he received chemotherapy (fotemustine 100 mg/m2 plus dacarbazine 900 mg/m2 intravenously, every three weeks, for a total of nine cycles) and in September 2006 the patient is alive with no evidence of disease (Figure 4, 5).